If not administered properly, health experts say medications like Ozempic, Mounjaro, and Wegovy can cause gastrointestinal ...

(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...

The study was small — just 48 adults — and lasted just over two months, so it’s not the final word. But the results add to evidence that GLP-1 drugs like Ozempic might help with cravings for things ...

The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

The weight of being a Hollywood star can take a toll on a person’s weight.In an industry obsessed with physical appearance, a ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...